News and Trends 2 Nov 2017 Swedish Biotech Team Steps Up in the Fight Against Type 2 Diabetes Two Swedish biotechs, Betagenon and Baltic Bio, have announced promising preliminary Phase IIa results for their Type 2 Diabetes candidate. Betagenon develops therapies for chronic energy balance disorders and has… November 2, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 4 Oct 2023 CAR-NK: Can natural killer cell therapy pick up from where CAR-T left off? …drug (IND) status for its drug candidate AB-201, a CAR-NK therapy for the treatment of solid tumors. AB-201 became the first CAR-NK therapy candidate to tend to HER2-positive cancer indications,… October 4, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 5 Feb 2018 New Antiviral for RSV Lung Infections Shows Promise in Phase IIa ReViral’s candidate RV521 showed its potential for the treatment of respiratory syncytial virus (RSV) infections by reducing viral load and mucus levels. London-based biotech ReViral discovers and develops antiviral drugs,… February 5, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 31 Jan 2024 New epilepsy drugs: what is in the pipeline? …a global phase 3 program. Cell therapy candidate for drug-resistant epilepsy Based in South San Francisco, biotech company Neurona Therapeutics is currently developing an allogeneic cell therapy candidate for the… January 31, 2024 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2023 First patient treated in Atrogi type 2 diabetes clinical study Atrogi AB, an early-stage Swedish pharma company, has announced that the first patient has been enrolled in a phase 1a/b study. Atrogi’s drug candidate, ATR-258 is a first in class… January 26, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 16 Nov 2023 uniQure: is the gene therapy pioneer en route to becoming a biotech rebuff? …candidate sees mixed results, uniQure stocks drop In the meantime, uniQure was invested in bringing its Huntington’s disease candidate to the market. AMT-130 consists of an adeno-associated virus serotype 5… November 16, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 14 Mar 2024 Rett syndrome: advances in gene therapy brings hope …is done by regulating the gene’s expression on a cell-by-cell basis. The candidate TSHA-102 is designed to mediate levels of MeCP2 proteins in the central nervous system without the risk… March 14, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 25 Jun 2025 ALS: how close are we to a cure? …patients, or slow disease progression. Even preclinical treatments such as the gene therapy candidate VY9323 have stumbled, but for different reasons. Massachusetts-based Voyager Therapeutics reported that its SOD1 gene-silencing candidate… June 25, 2025 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2021 Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells …based on immune cells known as gamma delta T cells. The proceeds of the IPO will be used to drive the development of the company’s pipeline of bispecific antibody drugs,… March 31, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Interview 10 May 2021 The Rollercoaster of Repurposing an Arthritis Drug for Covid-19 …position. Shortly after, the company started a program for Covid-19 based on its rheumatoid arthritis drug candidate. With the help of COO Malin Berthold, who had joined Cyxone in August… May 10, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
More News! 23 Jul 2024 First AKT-targeting drug capivasertib to hit the market, could it open the door for more? …clinical trials? Here are a couple of promising candidates in the AKT inhibitor space: Taiho Pharmaceuticals’ TAS-117 Currently in phase 1 clinical trials and tested in patients with advanced solid… July 23, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2021 Oxford’s Covid-19 Vaccine Blazes Trail for Oncolytic Virus Firms …advanced candidate — a liver cancer treatment developed by the French biotech Transgene — was abandoned in phase III in 2019. Why have new oncolytic viruses been slow to reach… January 26, 2021 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email